• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Triple antiviral treatment for COVID-19 in an immunocompromised patient.

作者信息

Dentone Chiara, Mikulska Malgorzata, Sepulcri Chiara, Balletto Elisa, De Pace Vanessa, Beltramini Sabrina, Bassetti Matteo

机构信息

Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore, 1, 16132 Genoa, Italy.

出版信息

J Antimicrob Chemother. 2023 Aug 2;78(8):2097-2099. doi: 10.1093/jac/dkad159.

DOI:10.1093/jac/dkad159
PMID:37229548
Abstract
摘要

相似文献

1
Triple antiviral treatment for COVID-19 in an immunocompromised patient.对一名免疫功能低下的新冠肺炎患者进行三联抗病毒治疗。
J Antimicrob Chemother. 2023 Aug 2;78(8):2097-2099. doi: 10.1093/jac/dkad159.
2
Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient.免疫功能低下患者中 SARS-CoV-2 的病毒持续排出。
J Infect Chemother. 2021 Feb;27(2):387-389. doi: 10.1016/j.jiac.2020.12.001. Epub 2020 Dec 4.
3
Test of 5- Versus 10-Day Remdesivir Treatment in Immunocompromised Patients With Coronavirus Disease 2019.针对2019冠状病毒病免疫功能低下患者的瑞德西韦5天与10天治疗试验。
Clin Infect Dis. 2023 Mar 21;76(6):1154-1155. doi: 10.1093/cid/ciac877.
4
Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host.免疫功能低下宿主持续性 2019 冠状病毒病与相关机化性肺炎的双联抗病毒治疗。
Clin Infect Dis. 2023 Mar 4;76(5):923-925. doi: 10.1093/cid/ciac847.
5
Does interval time between liver transplant and COVID-19 infection make the difference?肝移植与新冠病毒感染之间的间隔时间有影响吗？
Dig Liver Dis. 2021 Feb;53(2):169-170. doi: 10.1016/j.dld.2020.08.027. Epub 2020 Aug 25.
6
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。
Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.
7
Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients.奈玛特韦/利托那韦作为免疫功能低下患者长期感染新型冠状病毒的潜在治疗方法。
Rev Esp Quimioter. 2022 Dec;35(6):589-591. doi: 10.37201/req/078.2022. Epub 2022 Oct 18.
8
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19.针对 SARS-CoV-2 的治疗与 COVID-19 免疫功能低下患者的死亡率降低有关。
J Antimicrob Chemother. 2022 Sep 30;77(10):2688-2692. doi: 10.1093/jac/dkac253.
9
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.六位免疫功能低下的 COVID-19 患者中，高滴度恢复期血浆联合奈玛特韦/利托那韦治疗后仍未缓解。
J Antimicrob Chemother. 2023 Jul 5;78(7):1644-1648. doi: 10.1093/jac/dkad144.
10
Benign COVID-19 in an immunocompromised cancer patient -  the case of a married couple.免疫功能低下的癌症患者中的良性 COVID-19 - 一对夫妇的病例。
Swiss Med Wkly. 2020 Apr 11;150:w20246. doi: 10.4414/smw.2020.20246. eCollection 2020 Apr 6.

引用本文的文献

1
Antiviral combination treatment of SARS-CoV-2 after repeated treatment failures of remdesivir monotherapy: A case report.瑞德西韦单药反复治疗失败后对严重急性呼吸综合征冠状病毒2进行抗病毒联合治疗：一例报告
IDCases. 2024 Nov 13;38:e02118. doi: 10.1016/j.idcr.2024.e02118. eCollection 2024.
2
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients.奥密克戎时代血液系统恶性肿瘤患者的严重急性呼吸综合征冠状病毒2感染：血清阴性和血清阳性患者的呼吸衰竭、机械通气需求及死亡率
EJHaem. 2024 Apr 9;5(3):505-515. doi: 10.1002/jha2.867. eCollection 2024 Jun.